EORTC Presentations at ASCO 2017 in Chicago

EORTC will be presenting one oral abstract session, three abstracts in poster sessions and two publications at the ASCO Annual Meeting (June 2-6, 2017) in Chicago.

Oral presentations

• Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion. (Abstract 2009)

  Citation: J Clin Oncol 35, 2017
  Session: Maximizing the Approach to Central Nervous System Tumors
  Time: Saturday June 3, 3:00 to 4:30 PM
  Location: S102

Poster sessions

• EORTC1527/JCOG1609int: diffusion-weighted magnetic resonance imaging (DW-MRI) assessment of liver metastasis to improve surgical planning (DREAM) (Abstract TPS3633)

  Citation: J Clin Oncol 35, 2017
  Session: Gastrointestinal (Colorectal) Cancer
  Time: Saturday June 3, 8:00 to 11:30 AM
  Location: Hall A
  Authors: Kozo Kataoka, Carmela Aves Caballero, Laurence Collette, Kenichi Nakamura, Yoji Kishi, Patrick Starlinger, Hiroaki Onaya, Takeshi Suto, Michel Ducreux, Yasuhiro Shimada, Sabine Tejpar, Laura Rubbia-brandt, Gina Brown, Manabu Shiozawa, Serge Evrard

• Standard anthracycline-based vs. Docetaxel-Capecitabine in early breast cancer: results from the chemotherapy randomization (R-C) of EORTC 10041/ BIG 3-04 MINDACT phase III trial. (Abstract 516)

  Citation: J Clin Oncol 35, 2017
  Session: Breast Cancer – Local/ Regional/ Adjuvant
  Time: Sunday June 4, 8:00 to 11:30 AM
  Location: Hall A
  Session: Breast Cancer – Local/ Regional/ Adjuvant
  Time: Sunday June 4, 11:30 AM to 12:45 PM
  Location: Hall D2
  Authors: Fatima Cardoso, Martine J. Piccart-Gebhart, Emiel J. Rutgers, Saskia Litière, Laura Van’t Veer, Giuseppe Viale, Jean-Yves Pierga, Franchette W.P.J. van den Berkmortel, Etienne Brain, Patricia Gomez, Theodora Goulioti, Susan Knox, Elisabeth Luporsi, Ulrike Nitz, Isabel T Rubio, Lisette Stork, Peter Vuylsteke, Konstantinos Tryfonidis, Jan Bogaerts, Suzette delaloge

• RECIST 1.1 validated not only for cytotoxic agents but also for targeted cancer agents (TCA): results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database (Abstract 2534)

  Citation: J Clin Oncol 35, 2017
  Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
  Time: Monday June 5, 8:00 to 11:30 AM
  Location: Hall A
  Authors: Saskia Litière, Gaëlle Isaac, Elisabeth De Vries, Jan Bogaerts, Alice Chen, Janet Dancey, Robert Ford, Stephen Gwyther, Otto Hoekstra, Erich Huang, Nancy Lin, Yan Liu, Sumithra Mandrekar, Lawrence H Schwartz, Lalitha Shankar, Patrick Therasse, Lesley Seymour, On behalf of the RECIST Working Group

Publication-only abstracts

• Prognostic impact of primary tumor location in advanced urothelial carcinoma; the EORTC series. (Abstract e16034)

  Citation: J Clin Oncol 35, 2017
  Authors: Marco Moschini, Shahrokh F. Shariat, Maria De Santis, Joaquim Bellmunt, Cora N. Sternberg, Bertrand F. Tombal, Laurence Collette, Morgan Roupret; Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Medical University of Vienna, Vienna, Austria; LBI-ACR Vienna, Kaiser Franz Josef Hospital, Center for Oncology and Hematology, Vienna, Austria; Dana-Farber Cancer Institute, Boston, MA; San Camillo Forlanini Hospital, Rome, Italy; Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium; EORTC, Brussels, Belgium; Urology University Paris 6, Paris, France

• Cancer events in Belgian nursing home residents (NHR): An EORTC prospective cohort study. (Abstract e13066)

  Citation: J Clin Oncol 35, 2017
  Authors: Hans Wildiers, Monique Elseviers, Murielle E. Mauer, Jonas de Wolf, Edith Bastiaens, Sigrid Hatse, Marije Hamaker, Frank Buntinx, Jan de Lepeleire, Geert Uytterschaut, Konstantinos Tryfonidis, Maryska Janssen-Heijnen; University Hospitals Leuven, Leuven, Belgium; Centre for Research and Innovation in Care (CRIC), Faculty of Medicine and Health Care Sciences, University of Antwerp, Antwerp, Belgium; EORTC, Brussels, Belgium; Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, Leuven, Belgium; Department of Geriatric Medicine, Utrecht, Netherlands; Department of General Practice, Universities of Leuven and Maastricht, Leuven, Belgium; Departement of General Practice and University Psychiatric Hospital KU Leuven, Leuven, Belgium; Armonea, Belgium, Mechelen, Belgium; Department of Clinical Epidemiology, VieCuri Medical Centre, and the Maastricht University Medical Center+, GROW School for Oncology and Developmental Biology, Maastricht, Netherlands